Tiagabine for Cocaine Dependence in Methadone Treatment
噻加宾治疗美沙酮治疗中的可卡因依赖
基本信息
- 批准号:7228946
- 负责人:
- 金额:$ 30.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-15 至 2009-04-30
- 项目状态:已结题
- 来源:
- 关键词:4-Aminobutyrate aminotransferaseAbstinenceAgeAnimalsAnxietyAttenuatedBaclofenBehaviorBehavior TherapyClinical TrialsCocaineCocaine AbuseCocaine DependenceCognitive TherapyConsumptionDataDopamineDoseDouble-Blind MethodGABA transporterGABA-B ReceptorHIVHepatitis CHeroinHourIndividualInstitutionInterventionLabelMethadoneNumbersOpiate AddictionOpiatesOpioidOutcomeParticipantPatient Self-ReportPatientsPersonal SatisfactionPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPilot ProjectsPlacebo ControlPlacebosPopulationPositioning AttributePsychotherapyRandomizedRandomized Clinical TrialsRateRelapseRelative (related person)ReportingResearchRiskRoleSafetySerotoninSubstance abuse problemSupervisionSymptomsSystemTestingTrainingTreatment EfficacyTreatment outcomeUrinalysisVigabatrinWeekWithdrawal SymptomWorkbasedaydesignexperiencefollow-upgabapentingamma-Aminobutyric Acidinhibitor/antagonistneurotransmissionpreclinical studypsychosocialreuptaketiagabinetreatment durationuptake
项目摘要
DESCRIPTION (provided by applicant): No effective pharmacological treatment for cocaine dependence has yet been developed. Comorbid cocaine dependence among methadone maintained patients interferes with treatment outcomes, and increases the risk of relapse to IV use, which is associated with increased risk for HIV and Hepatitis C. Enhanced GABA eurotransmission appears to attenuate cocaine's reinforcing effects. The objective of this proposal is to examine to what extend will enhancing the GABA system modify cocaine-using behavior and attenuate opiate withdrawal symptoms among newly admitted methadone treated patients. The primary hypothesis is that enhancing the GABA system with a GABA transporter blocker tiagabine we expect to reduce cocaine use and to promote abstinence in cocaine abusing methadone treated patients. The secondary hypothesis is that enhancing the GABA system with a GABA transporter blocker tiagabine we expect to attenuate early opiate withdrawal symptoms in newly admitted methadone treated patients. These hypotheses are formulated based on our pilot studies using the selective GABA re-uptake inhibitor tiagabine.
This 14-week double-blind, placebo controlled randomized clinical trial will provide treatment for 120 cocaine and opioid dependent patients. Participants, aged 18-65 years, will be randomized to receive tiagabine 32mg/day, tiagabine 20mg/day or placebo while concurrently receiving treatment with methadone. All participants receive weekly 1-hour individual psychotherapy (Cognitive Behavioral Therapy) with experienced clinicians specifically trained to deliver the therapy and who will receive ongoing supervision. A follow-up at 3 months will allow us to evaluate opioid and cocaine use, and changes in psychosocial adjustment. The primary outcomes will be abstinence rates and reduction in opioid and cocaine use, as assessed by self-report and thrice-weekly urinalyses. The proposed study is expected to provide a better understanding of the role of the selective GABA re-uptake inhibitor tiagabine on cocaine using behavior and treatment of opiate withdrawal symptoms, and will provide valuable information to develop new pharmacological interventions for comorbid cocaine dependence among methadone treated patients.
描述(由申请人提供):没有有效的药物治疗可卡因依赖尚未开发。维持美沙酮的患者的合并症可卡因依赖会干扰治疗结果,并增加静脉注射的复发风险,这与艾滋病毒和丙型肝炎的风险增加有关。增强的GABA神经传播似乎减弱了可卡因的强化作用。本研究旨在探讨GABA系统的增强对新入院美沙酮治疗患者的可卡因使用行为和阿片戒断症状的影响。主要的假设是,使用GABA转运体阻滞剂替加滨增强GABA系统,我们期望减少可卡因的使用,并促进可卡因滥用美沙酮治疗患者的戒断。第二个假设是,使用GABA转运体阻滞剂替加滨增强GABA系统,我们期望减轻新入院美沙酮治疗患者的早期阿片类戒断症状。这些假设是基于我们使用选择性GABA再摄取抑制剂替加滨的初步研究而制定的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gerardo Gonzalez其他文献
Gerardo Gonzalez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gerardo Gonzalez', 18)}}的其他基金
Supporting Treatment Access and Recovery for Co-Occurring Opioid Use and Mental Health Disorders (STAR-COD)
支持同时发生的阿片类药物使用和精神健康障碍的治疗获取和康复 (STAR-COD)
- 批准号:
10373400 - 财政年份:2021
- 资助金额:
$ 30.52万 - 项目类别:
Supporting Treatment Access and Recovery for Co-Occurring Opioid Use and Mental Health Disorders (STAR-COD)
支持同时发生的阿片类药物使用和精神健康障碍的治疗获取和康复 (STAR-COD)
- 批准号:
10489842 - 财政年份:2021
- 资助金额:
$ 30.52万 - 项目类别:
Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
美金刚增强丁丙诺啡治疗阿片类药物依赖的年轻人
- 批准号:
8075095 - 财政年份:2009
- 资助金额:
$ 30.52万 - 项目类别:
Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
美金刚增强丁丙诺啡治疗阿片类药物依赖的年轻人
- 批准号:
7884316 - 财政年份:2009
- 资助金额:
$ 30.52万 - 项目类别:
Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
美金刚增强丁丙诺啡治疗阿片类药物依赖的年轻人
- 批准号:
7715005 - 财政年份:2009
- 资助金额:
$ 30.52万 - 项目类别:
Tiagabine for Cocaine Dependence in Methadone Treatment
噻加宾治疗美沙酮治疗中的可卡因依赖
- 批准号:
6920040 - 财政年份:2004
- 资助金额:
$ 30.52万 - 项目类别:
Tiagabine for Cocaine Dependence in Methadone Treatment
噻加宾治疗美沙酮治疗中的可卡因依赖
- 批准号:
6762054 - 财政年份:2004
- 资助金额:
$ 30.52万 - 项目类别:
Tiagabine for Cocaine Dependence in Methadone Treatment
噻加宾治疗美沙酮治疗中的可卡因依赖
- 批准号:
7060962 - 财政年份:2004
- 资助金额:
$ 30.52万 - 项目类别:
Tiagabine and Disulfiram for Cocaine Dependence
噻加宾和双硫仑治疗可卡因依赖
- 批准号:
6830601 - 财政年份:2004
- 资助金额:
$ 30.52万 - 项目类别:
Comorbid Disorders in Treatment of Opiate Dependence
阿片依赖治疗中的共病
- 批准号:
6781016 - 财政年份:2001
- 资助金额:
$ 30.52万 - 项目类别:
相似海外基金
StuDy AimED at Increasing AlCohol AbsTinEnce (DEDICATE)
旨在提高酒精戒断率的研究(奉献)
- 批准号:
10577022 - 财政年份:2023
- 资助金额:
$ 30.52万 - 项目类别:
A Controlled Study of Extended Cannabis Abstinence in Major Depression
重度抑郁症患者长期吸食大麻的对照研究
- 批准号:
478313 - 财政年份:2023
- 资助金额:
$ 30.52万 - 项目类别:
Operating Grants
Exercised-induced modulation of insular cortex microcircuitry during alcohol abstinence
戒酒期间运动诱导的岛叶皮质微电路调节
- 批准号:
10748763 - 财政年份:2023
- 资助金额:
$ 30.52万 - 项目类别:
Prapela™ SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.
Prapela™ SVS:一种经济高效的随机振动触觉刺激装置,可改善患有新生儿戒断综合征的婴儿的临床过程。
- 批准号:
10837421 - 财政年份:2023
- 资助金额:
$ 30.52万 - 项目类别:
Enforced alcohol abstinence: does it reduce reoffending?
强制戒酒:会减少再犯罪吗?
- 批准号:
ES/X003566/1 - 财政年份:2023
- 资助金额:
$ 30.52万 - 项目类别:
Fellowship
Neurobiological impact of acute digital media abstinence among drug using college students
吸毒大学生急性数字媒体戒断的神经生物学影响
- 批准号:
10677380 - 财政年份:2023
- 资助金额:
$ 30.52万 - 项目类别:
Single-cell whole brain imaging of nicotine intoxication, dependence, and abstinence
尼古丁中毒、依赖和戒断的单细胞全脑成像
- 批准号:
10588509 - 财政年份:2023
- 资助金额:
$ 30.52万 - 项目类别:
Understanding recovery from alcohol use disorder: Longitudinal observation of two voluntary temporary abstinence periods
了解酒精使用障碍的恢复:两个自愿临时戒酒期的纵向观察
- 批准号:
10740677 - 财政年份:2023
- 资助金额:
$ 30.52万 - 项目类别:
Sleep Disturbances During Cocaine Abstinence, Dopamine Adaptations, and Motivation for Cocaine
可卡因戒断期间的睡眠障碍、多巴胺适应和可卡因动机
- 批准号:
10681668 - 财政年份:2023
- 资助金额:
$ 30.52万 - 项目类别:
Relationship of autonomic nervous system function on functional brain networks during normal drinking and abstinence in daily drinkers
日常饮酒者正常饮酒和戒酒时自主神经系统功能与功能性脑网络的关系
- 批准号:
10540603 - 财政年份:2022
- 资助金额:
$ 30.52万 - 项目类别:














{{item.name}}会员




